The Department of Justice and U.S. Drug Enforcement Agency proposed to reduce manufacturing quotas for the six most frequently abused opioids by 10% in 2019 amid the historic epidemic.
The board of St. John's Riverside Hospital in Yonkers has voted to begin exclusive negotiations to join Montefiore Health System, four years after it entered a clinical affiliation with the health system.
A mobile fertility app is the first ever digital contraceptive device to win FDA marketing approval. But reports of unwanted pregnancies and investigations in Europe have raised questions about marketing what is essentially a health monitor as a contraceptive.
Providers worry that AI companies are moving too quickly, many doctors don't disclose medical device compensation in published studies, and Elon Musk struggles.
Many Democratic congressional hopefuls are making healthcare their top talking point for the upcoming midterm elections, which is not surprising given the low unemployment rate. The early donations from political action groups lean toward the incumbents.
Teva Pharmaceutical's product is the first direct generic copy of the EpiPen, the life-saving automatic epinephrine injector that fueled a national debate on rising pharmaceutical prices.
St. Louis-based SSM Health signed letters of intent to sell three of its Missouri hospitals to University of Missouri Health Care and Mosaic Life Care. The health system said it expects the due diligence process to take a few months.
NYU School of Medicine will provide free tuition to all current and future students to alleviate the burden of crippling debt on physicians. It's the first major medical school in the U.S. to provide free education to all students.
A special National Institutes of Health oversight panel will no longer review all gene therapy applications and will instead take on a broader advisory role, as the treatment quickly becomes an established form of medical care with no extraordinary risks.
As scrutiny tightens on drug middlemen and the significance of their role in spiking drug costs within Medicare Part D, health insurers are hitting back with data that show the most expensive drugs offer the lowest rebates.
The healthcare industry saw fewer bankruptcies in the second quarter of 2018 compared with the first, according to law firm Polsinelli, breaking with eight quarters of record or near-record highs. But one report author doesn't expect the lull to stick.
The owners of a New Hampshire provider stopped caring for 16 veterans as of Friday because they were unable to get about $60,000 in bills paid by the Veterans Affairs Department.